ClinicalTrials.gg

Program

trospium

Its studies are mostly in Alzheimer Disease · Schizophrenia · Mania · Autism Spectrum Disorder · Nausea, led by Bristol-Myers Squibb.

Furthest: phase 4, since Jun 26, 202621 company-led studies, 18 open or runningNext primary completion: Nov 24, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb2118 open or runningphase 4since Jun 26, 2026Aug 19, 2022Nov 24, 2026phase 3 · NCT06585787

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2022First study: phase 3 study in Psychosis Associated With Alzheimer's DiseaseFirst studyNCT05511363 · 410 planned · United States, Bulgaria, Croatia and more
  2. Jul 31, 2023Phase 3 study in Psychosis Associated With Alzheimer's DiseaseNCT05980949 · 1,000 planned · United States, Argentina, Belgium and more
  3. Nov 3, 2023Phase 3 study in Psychosis Associated With Alzheimer's DiseaseNCT06126224 · 500 planned · United States, Belgium, Canada and more
  4. Aug 8, 20242 phase 3 studiesNCT06572449, NCT06585787
  5. Sep 18, 2024Phase 1 study in Healthy VolunteersNCT06605950 · 78 enrolled · United States
  6. Feb 25, 2025Phase 1 study in Mental DisordersNCT06853171 · 24 enrolled · United States
  7. Mar 17, 2025Phase 3 study in SchizophreniaNCT06882785 · 250 planned · Japan
  8. Apr 14, 20255 phase 3 studiesNCT06929273, NCT06937229, NCT06951711 and 2 more
  9. May 9, 20252 phase 3 studies in Alzheimer DiseaseNCT06976216, NCT06976203
  10. Jul 2, 2025Phase 1 study in SchizophreniaNCT07061288 · 131 planned · United States
  11. Dec 9, 20253 phase 3 studiesNCT07284745, NCT07285798, NCT07288567
  12. Feb 13, 2026Phase 3 study in SchizophreniaNCT07424404 · 400 planned · United States, Australia, Canada and more
  13. Jun 26, 2026Phase 4 study in NauseaNCT07681076 · 180 planned · United States

Ahead

  1. Nov 1, 2026Primary completion: phase 3 study in ManiaNCT06951698
  2. Nov 2, 2026Primary completion: phase 3 study in ManiaNCT06951711
  3. Nov 24, 2026Primary completion: phase 3 study in Alzheimer DiseaseNCT06585787
  4. Nov 30, 2026Primary completion: phase 4 study in NauseaNCT07681076

TargetBeta

CHRM2 →CHRM3 →read by rule
“Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M2 antagonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
GlycopyrrolateruleNovartisphase 487
trospium chlorideruleBristol-Myers Squibbphase 415
AtropineruleLaboratorios Sophia S.A de C.V.phase 317

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07681076Nausea · United States4RecruitingNov 30, 2026180
NCT07424404Schizophrenia · United States, Australia, Canada and more3RecruitingMar 8, 2030400
NCT07288567Schizophrenia · United States, Colombia, Japan and more3RecruitingDec 18, 2029166
NCT07285798Autism Spectrum Disorder · United States, France, Germany and more3RecruitingAug 6, 2029176
NCT07284745Autism Spectrum Disorder · United States, Australia, Canada and more3RecruitingAug 6, 2029176
NCT07061288Schizophrenia · United States1RecruitingJun 21, 2027131
NCT06976216Alzheimer Disease · United States, Argentina, Australia and more3RecruitingSep 11, 2028586
NCT06976203Alzheimer Disease · United States, Argentina, Australia and more3RecruitingSep 11, 2028586
NCT06947941Alzheimer Disease · United States, Australia, Canada and more3RecruitingFeb 21, 2028325
NCT06951711Mania · United States, China, Croatia and more3RecruitingNov 2, 2026274
NCT06951698Mania · United States, Argentina, Australia and more3RecruitingNov 1, 2026274
NCT06937229Alzheimer Disease · United States, Argentina, Brazil and more3RecruitingJun 22, 2029650
NCT06929273Mania · United States, Argentina, Australia and more3RecruitingJun 13, 2028450
NCT06882785Schizophrenia · Japan3RecruitingSep 23, 2028250
NCT06853171Mental Disorders · United States1CompletedJul 22, 202524
NCT06605950Healthy Volunteers · United States1CompletedMay 31, 202578
NCT06585787Alzheimer Disease · United States, Argentina, Belgium and more3RecruitingNov 24, 2026406
NCT06572449Schizophrenia · United States3CompletedMar 13, 2025173
NCT06126224Psychosis Associated With Alzheimer's Disease · United States, Belgium, Canada and more3RecruitingDec 9, 2026500
NCT05980949Psychosis Associated With Alzheimer's Disease · United States, Argentina, Belgium and more3RecruitingSep 7, 20271,000
NCT05511363Psychosis Associated With Alzheimer's Disease · United States, Bulgaria, Croatia and more3RecruitingOct 5, 2026410

How it is read

Names in the registry

  • “KarXT”, 21 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.